Bruderman Asset Management, LLC Aeterna Zentaris Inc. Transaction History

Bruderman Asset Management, LLC

  • $55.7 Million
  • Q2 2022

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2019

Aug 12, 2019
SELL
$2.04 - $5.43 $6 - $16
-3 Closed
0 $0
Q4 2018

Feb 11, 2019
BUY
$1.3 - $3.87 $3 - $11
3 New
3 $0

About Aeterna Zentaris Inc.

AEZS Quotes by TradingView
  • Ticker AEZS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 4,855,880
  • Market Cap $19.4M
  • Description
  • Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult grow...
More about AEZS
Track This Portfolio

Track Bruderman Asset Management, LLC Portfolio

Follow Bruderman Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bruderman Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Bruderman Asset Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email